• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Quart Barry D claimed ownership of 224,034 units of Ordinary Shares (SEC Form 3)

    3/16/26 4:47:00 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CNTB alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Quart Barry D

    (Last) (First) (Middle)
    3580 CARMEL MOUNTAIN ROAD, SUITE 200

    (Street)
    SAN DIEGO CA 92130

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    03/16/2026
    3. Issuer Name and Ticker or Trading Symbol
    Connect Biopharma Holdings Ltd [ CNTB ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Executive Officer
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Ordinary Shares 95,147 D
    Ordinary Shares 128,887 I By Joint Account with Spouse
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Employee Stock Option (Right to Buy) (1) 06/12/2034 Ordinary Shares 2,658,734 $1.77 D
    Employee Stock Option (Right to Buy) (1) 12/26/2034 Ordinary Shares 432,392 $0.97 D
    Employee Stock Option (Right to Buy) (2) 12/26/2035 Ordinary Shares 700,000 $2.69 D
    Explanation of Responses:
    1. The stock option vests and becomes exercisable over four years, with 25% vesting on the first anniversary of the date of grant, and then with respect to the remaining shares on a ratable monthly basis over the next three years, subject to continuous service with the Company as of each applicable vesting date.
    2. The stock option vests and becomes exercisable on a ratable monthly basis over four years, subject to continuous service with the Company as of each applicable vesting date.
    Remarks:
    /s/ Lisa Peraza attorney-in-fact for Barry D Quart 03/16/2026
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CNTB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CNTB

    DatePrice TargetRatingAnalyst
    12/1/2025$9.00Buy
    Lake Street
    10/31/2025$10.00Buy
    BTIG Research
    6/12/2025$7.00Buy
    H.C. Wainwright
    3/4/2024$7.00Buy
    H.C. Wainwright
    More analyst ratings

    $CNTB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Connect Biopharma with a new price target

    Lake Street initiated coverage of Connect Biopharma with a rating of Buy and set a new price target of $9.00

    12/1/25 9:37:24 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on Connect Biopharma with a new price target

    BTIG Research initiated coverage of Connect Biopharma with a rating of Buy and set a new price target of $10.00

    10/31/25 8:19:20 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Connect Biopharma with a new price target

    H.C. Wainwright initiated coverage of Connect Biopharma with a rating of Buy and set a new price target of $7.00

    6/12/25 7:54:22 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting

    SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect, or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that the results of a Phase 3 study of rademikibart in moderate-to-severe atopic dermatitis (AD) conducted by the Company's partner in China, Simcere Pharmaceutical Co., Ltd. (Simcere), will be presented in the Late-Breaking Research session at the 2026 AAD Annual Meeting, which takes place March 27-31, 2026, in Denver, Colorado. "We are very encouraged by the acceptance of our partner's Phase 3 atopic dermatitis study f

    3/10/26 9:00:00 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Connect Biopharma to Present at the Leerink Partners Global Healthcare Conference

    SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma", "Connect", or the "Company"), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Tuesday, March 10, 2026 at 8:00 a.m. ET. The live webcast of the presentation may be accessed via the Investors section of the Connect website at investors.connectbiopharma.com. An archived replay of the event will be available on the website for approximately 90 days following the conference. About

    3/3/26 9:00:00 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Connect Biopharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

    SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma", "Connect", or the "Company"), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26th, 2026 at 2:40 p.m. ET. The live webcast of the presentation may be accessed via the Investors section of the Connect website at investors.connectbiopharma.com. An archived replay of the event will be available on the website for approximately 90 days following the conference. About Conn

    2/19/26 9:00:00 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Szekeres David Leslie claimed ownership of 215,739 units of Ordinary Shares (SEC Form 3)

    3 - Connect Biopharma Holdings Ltd (0001835268) (Issuer)

    3/16/26 4:47:35 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Quart Barry D claimed ownership of 224,034 units of Ordinary Shares (SEC Form 3)

    3 - Connect Biopharma Holdings Ltd (0001835268) (Issuer)

    3/16/26 4:47:00 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Peraza Lisa claimed ownership of 45,189 units of Ordinary Shares (SEC Form 3)

    3 - Connect Biopharma Holdings Ltd (0001835268) (Issuer)

    3/16/26 4:46:04 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTB
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Connect Biopharma Holdings Limited

    SCHEDULE 13G - Connect Biopharma Holdings Ltd (0001835268) (Subject)

    2/17/26 5:22:24 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Connect Biopharma Holdings Limited filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Connect Biopharma Holdings Ltd (0001835268) (Filer)

    12/23/25 4:32:02 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Connect Biopharma Holdings Limited

    10-Q - Connect Biopharma Holdings Ltd (0001835268) (Filer)

    11/12/25 9:04:30 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTB
    Leadership Updates

    Live Leadership Updates

    View All

    Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors

    – Mr. Schoeneck is a seasoned industry executive and director with deep expertise in development and commercialization of breakthrough products and guiding companies through significant transformation and growth – SAN DIEGO, July 22, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect, or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced the expansion of the size of its Board of Directors from six to seven directors and the appointment of Jim Schoeneck as a director effective today. "We are pleased to welcome Jim to our Board of Directors," sai

    7/22/25 9:00:00 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Attovia Therapeutics Appoints Chief Financial Officer

    FREMONT, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics announced the appointment of Steven Chan as Chief Financial Officer. Mr. Chan brings extensive financial strategy and operational experience and joins Attovia after serving as Chief Financial Officer at Connect Biopharma (NASDAQ:CNTB), a global clinical-stage biopharmaceutical company focused on T cell-driven therapeutics for inflammatory diseases. At Attovia, Mr. Chan will lead the company's finance and operations functions and serve on its Executive Committee, reporting to Tao Fu, Chief Executive Officer. "I am delighted to welcome Steve to Attovia at this critical growth period for the company. He brings over thirt

    10/15/24 7:30:00 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update

    Announced new U.S.-based leadership with the appointment of Barry Quart, Pharm.D. as Chief Executive Officer (CEO) and David Szekeres as PresidentConnect's new management is currently evaluating the future clinical development strategy for rademikibartAs part of Connect's transformation into a U.S.-centric company, the Company will be significantly reducing its presence in ChinaCash and cash equivalents of $110.2 million expected to support planned operations into at least the first half of 2027 SAN DIEGO, CA, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma," "Connect" or the "Company"), a U.S.-headquartered global clinical-stage bio

    9/5/24 4:05:00 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Connect Biopharma Holdings Limited

    SC 13D/A - Connect Biopharma Holdings Ltd (0001835268) (Subject)

    7/1/24 4:16:48 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Connect Biopharma Holdings Limited (Amendment)

    SC 13D/A - Connect Biopharma Holdings Ltd (0001835268) (Subject)

    2/27/24 9:00:28 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Connect Biopharma Holdings Limited (Amendment)

    SC 13D/A - Connect Biopharma Holdings Ltd (0001835268) (Subject)

    2/27/24 4:19:26 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTB
    Financials

    Live finance-specific insights

    View All

    Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma

    The global trial met its primary endpoint showing both doses of rademikibart treatment significantly improved lung function at Week 12The significant improvement in lung function was observed as early as Week 1 and was sustained through Week 24 with both doses of rademikibartSignificant improvement in asthma control occurred early and was sustained through Week 24 for both doses of rademikibartSafety results suggest rademikibart was generally well toleratedA conference call and webcast presentation to discuss the data will be held today at 8:30 a.m. ET, details below SAN DIEGO, CA and TAICANG, China, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:

    12/12/23 6:00:00 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023

    SAN DIEGO, CA and TAICANG, China, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that it will present top-line data from the global Phase 2b trial evaluating rademikibart's efficacy and safety in patients with moderate-to-severe asthma on Tuesday, December 12, 2023, prior to market open. Following the announcement, the Company will host a conference call and webcast presentation at 8:30 a.m. ET to d

    12/11/23 4:05:21 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis

    Clinical response (IGA 0/1 and EASI-75) achieved at Week 16 with rademikibart treatment was maintained through Week 52 with both every two weeks (Q2W) and every four weeks (Q4W) dosing regimens Approximately 90% of patients on Q4W dose maintained both IGA 0/1 and EASI-75 through Week 52 Over 36 weeks of treatment in Stage 2 of the study, the percentage of patients achieving IGA 0/1 and EASI-75 continued to increaseRademikibart continued to be well tolerated over 52 weeks of treatmentA conference call and webcast presentation to discuss the data will be held today at 8:30 a.m. ET, details below SAN DIEGO, CA and TAICANG, China, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings L

    11/21/23 6:00:00 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care